Kashif Irfan, MD
Interventional Pain Medicine · Mesquite, TXNPI 1851351977
Payments from drug & device makers
Across 1,132 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Medtronic$2K
- Boston Scientific$2K
- Forte Bio-pharma LLC$2K
- Spinal Simplicity, LLC$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- plus $14K from 53 others
What the payments were for
- Travel & lodging$5612%
- Food & beverage$25,03397%
- Education$710%
- Gifts$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$1,200
- WaveWriter Alpha Prime 16$971
- HA MINUTEMAN G3-R$967
- Proclaim Family of SCS IPGs$854
- Prolate$849
- LIBERTY SI$649
- INTELLIS$574
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$551
- NURTEC ODT$500
- mild Device Kit$415
- Nalocet$368
- UBRELVY$358
- Intracept$327
- Senza$260
- AJOVY$249
- AIMOVIG$247
- Zilretta$240
- Octrode SCS Leads$239
- Qutenza$232
- SPECTRA WAVEWRITER$219
How this compares
$25,681 in reported general payments places this provider in the 80th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Potassium | 133 | $409,880 |
| PercocetOxycodone Hcl/Acetaminophen | 11 | $91,485 |
| RelistorMethylnaltrexone Bromide | 29 | $69,248 |
| BelbucaBuprenorphine Hcl | 86 | $62,579 |
| Nurtec OdtRimegepant Sulfate | 34 | $53,155 |
| Nucynta ErTapentadol Hcl | 45 | $52,357 |
| ProlateOxycodone Hcl/Acetaminophen | 16 | $43,853 |
| ZtlidoLidocaine | 57 | $42,824 |
| Xtampza ErOxycodone Myristate | 43 | $42,137 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,120 | $37,459 |
| NucyntaTapentadol Hcl | 24 | $37,041 |
| QuliptaAtogepant | 26 | $28,245 |
| Diclofenac Sodium | 71 | $22,447 |
| OxycontinOxycodone Hcl | 22 | $19,198 |
| Piroxicam | 34 | $16,801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er, Xtampza Er, Nucynta | $1,270 | $194,113198 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $1,457 | $69,24829 claims |
| PfizerNurtec Odt, Zavzpret | $865 | $67,68348 claims |
| AbbVieQulipta, Ubrelvy | $1,432 | $44,65837 claims |
| Forte Bio-pharma LLCProlate | $1,690 | $43,85316 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $1,088 | $42,82457 claims |
| Redhill Biopharma Inc.Movantik | $50 | $13,96033 claims |
| Hikma Pharmaceuticals USABuprenorphine Hcl | $60 | $7,113155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 287 interventional pain medicine providers in Texas.
Other interventional pain medicine in Mesquite
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.2M
- Genaro GutierrezAustin$1.3M
- Chad StephensSouthlake$1.1M
- Ioannis SkaribasHouston$979K
- Duane GriffithTyler$730K
- Brannon FrankAustin$698K
- Robert WillsRound Rock$692K
- Ankur KhoslaShenandoah$511K
- Brian RichDecatur$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.